Chemical-induced liver injury can be manifested in a number of ways, such as cholestasis, steatosis, fibrosis, and cancer. The mechanisms driving these toxicological processes have been well characterized and have been embedded in adverse outcome pathway frameworks in recent years. This article provides a concise overview of these constructs.
Get full access to this article
View all access options for this article.
References
1.
VinkenM, MaesM, VanhaeckeT, et al.Drug-induced liver injury: Mechanisms, types and biomarkers. Curr Med Chem, 2013:20; 3011–3021.
Van den HofWF, Ruiz-AracamaA, Van SummerenA, et al.Integrating multiple omics to unravel mechanisms of cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro, 2015:29; 489–501.
4.
VinkenM, PauwelsM, AtesG, et al.Screening of repeated dose toxicity data present in SCC(NF)P/SCCS safety evaluations of cosmetic ingredients. Arch Toxicol, 2012:86; 405–412.
5.
LavertyHG, AntoineDJ, BensonC, et al.The potential of cytokines as safety biomarkers for drug-induced liver injury. Eur J Clin Pharmacol, 2010:66; 961–976.
6.
OzerJ, RatnerM, ShawM, et al.The current state of serum biomarkers of hepatotoxicity. Toxicology, 2008:245; 194–205.
7.
AnkleyGT, BennettRS, EricksonRJ, et al.Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem, 2010:29; 730–741.
8.
VilleneuveDL, CrumpD, Garcia-ReyeroN, et al.Adverse outcome pathway (AOP) development I: Strategies and principles. Toxicol Sci, 2014:14; 312–320.
9.
VilleneuveDL, CrumpD, Garcia-ReyeroN, et al.Adverse outcome pathway development II: Best practices. Toxicol Sci, 2014:14; 321–330.
SchoemakerMH, Conde de la RosaL, Buist-HomanM, et al.Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology, 2004:39; 1563–1573.
12.
WoolbrightBL, JaeschkeH. Novel insight into mechanisms of cholestatic liver injury. World J Gastroenterol, 2012:18; 4985–4993.
13.
HofmannAF. Bile acids and the enterohepatic circulation. In: The Liver: Biology and Pathobiology. AriasIM, AlterHJ, BoyerJL, CohenDE, austoNF, ShafritzDA, WolkoffAW (eds); pp. 289–204. Oxford: Wiley-Blackwell; 2009.
14.
PaddaMS, SanchezM, AkhtarAJ, et al.Drug-induced cholestasis. Hepatology, 2011:53; 1377–1387.
15.
ZollnerG, TraunerM. Molecular mechanisms of cholestasis. Wien Med Wochenschr, 2006:156; 380–385.
16.
ZollnerG, TraunerM. Mechanisms of cholestasis. Clin Liver Dis, 2008:12; 1–26.
17.
WagnerM, ZollnerG, TraunerM. New molecular insights into the mechanisms of cholestasis. J Hepatol, 2009:51; 565–580.
18.
FriedmanSL. Mechanisms of hepatic fibrogenesis. Gastroenterology, 2008:134; 1655–1669.
LeeUE, FriedmanSL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol, 2011:25; 195–206.
21.
VinkenM, KnapenD, VergauwenL, et al.Adverse outcome pathways: A concise introduction for toxicologists. Arch Toxicol, 2017:91; 3697–3707.
22.
MellorCL, SteinmetzFP, CroninMT. The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways. Crit Rev Toxicol, 2016:46; 138–152.
23.
AngrishMM, McQueenCA, Cohen-HubalE, et al.Editor's highlight: Mechanistic toxicity tests based on an adverse outcome pathway network for hepatic steatosis. Toxicol Sci, 2017:159; 159–169.
